Cellosaurus RPMI-8226/Dox6 (CVCL_J432)

Cell line name RPMI-8226/Dox6
Synonyms RPMI 8226/DOX6; 8226/DOX6; 8226/Dox6; DOX-6; Dox6
Accession CVCL_J432
Resource Identification Initiative To cite this cell line use: RPMI-8226/Dox6 (RRID:CVCL_J432)
Comments Characteristics: Produces IgG lambda.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from sampling site: Peripheral blood.
Sequence variations Heterozygous for EGFR p.Thr751Ile (c.2252C>T) (from parent cell line).
Heterozygous for KRAS p.Gly12Ala (c.35G>C) (from parent cell line).
Homozygous for TP53 p.Glu285Lys (c.853G>A) (from parent cell line).
Disease Plasma cell myeloma (NCIt: C3242)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0014 (RPMI-8226)
Sex of cell Male
Age at sampling 61Y
Category Cancer cell line
Publications

PubMed=2569359
Tong A.W., Lee J., Wang R.-M., Dalton W.S., Tsuruo T., Fay J.W., Stone M.J.
Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
Cancer Res. 49:4829-4834(1989)

PubMed=10070958
Hazlehurst L.A., Foley N.E., Gleason-Guzman M.C., Hacker M.P., Cress A.E., Greenberger L.M., De Jong M.C., Dalton W.S.
Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.
Cancer Res. 59:1021-1028(1999)

Cross-references
Other Wikidata; Q54951247